Synergy Pharmaceuticals

222 articles about Synergy Pharmaceuticals

• Synergy Pharma: A Hidden Gem In The BioPharma Sector

  8/16/2017

• Synergy Pharma Reports Second Quarter 2017 Financial Results And Business Update

  8/10/2017

• Synergy Pharma Announces Acceptance Of Supplemental New Drug Application (sNDA) For TRULANCE (Plecanatide) For The Treatment Of Adults With Irritable Bowel Syndrome With Constipation (IBS-C)

  6/6/2017

• Synergy Pharma Reports First Quarter 2017 Financial Results And Business Update

  5/11/2017

• Synergy Pharma To Present Positive TRULANCE (Plecanatide) Phase III Data At Digestive Disease Week (DDW) For The Treatment Of Irritable Bowel Syndrome With Constipation (IBS-C)

  5/10/2017

• Synergy Pharma To Present TRULANCE (Plecanatide) Phase III Data At Digestive Disease Week (DDW) For The Treatment Of Adults With Chronic Idiopathic Constipation (CIC) With Moderate To Very Severe Bloating

  5/8/2017

• Synergy Pharma Presents New Insights At Digestive Disease Week (DDW) Examining Patient And Physician Perceptions And Experiences With Chronic Idiopathic Constipation (CIC)

  5/8/2017

• Synergy Pharma To Highlight New Data For TRULANCE (Plecanatide) At Digestive Disease Week (DDW)

  5/1/2017

• Synergy Pharma Appoints Gary G. Gemignani As Chief Financial Officer

  4/17/2017

• Synergy Pharma Announces Issuance Of Three New Patents Expected To Extend TRULANCE (Plecanatide) Patent Protection Until 2032

  4/12/2017

• Synergy Pharma Launches The Poop Troop, The First Emoji Keyboard Designed To Support Dialogue Around Chronic Idiopathic Constipation (CIC)

  4/6/2017

• Synergy Pharma Submits Supplemental New Drug Application (sNDA) For TRULANCE (Plecanatide) For The Treatment Of Adults With Irritable Bowel Syndrome With Constipation (IBS-C)

  3/27/2017

• Synergy Pharma Reports Fourth Quarter And Full Year 2016 Financial Results And Business Update

  3/3/2017

• Synergy Pharma Reports Fourth Quarter And Full Year 2016 Financial Results And Business Update

  3/2/2017

• 50+ Valeant Sales Reps May Have Jumped Ship to Synergy Pharma

  2/24/2017

• Synergy Pharma Release: Pivotal Phase III Data Results For TRULANCE (Plecanatide) In The Treatment Of Chronic Idiopathic Constipation (CIC) Published In American Journal Of Gastroenterology

  2/7/2017

• Synergy Pharma Announces Proposed Public Offering Of Common Stock

  2/1/2017

• Synergy Pharma Announces Pricing Of Public Offering Of Common Stock

  2/1/2017

• Synergy Pharma Release: TRULANCE (Plecanatide) Receives U.S. FDA Approval For The Treatment Of Adults With Chronic Idiopathic Constipation

  1/20/2017

• Synergy Pharma Announces Positive Results In Second Phase 3 Trial Of Plecanatide In Patients With Irritable Bowel Syndrome With Constipation (IBS-C)

  12/27/2016